ARTHROPLASTY
Lower blood loss with IV+IA TXA versus IV TXA alone following total knee arthroplasty
J Bone Joint Surg Am. 2016 May 18;98(10):835-4160 patients scheduled for unilateral total knee arthroplasty were randomized to either combined intravenous and intra-articular tranexamic acid administration, or intravenous TXA administration alone. The purpose of this study was to determine if combined IV-IA TXA administration offered lower 24-hour blood loss compared to IV administration alone. In addition to significantly lower 24-hr blood loss noted in the combined IV-IA TXA group compared to the IV TXA group, 2-day blood loss was also significantly lower. Only one patient overall required transfusion, and no patient developed venous thromboembolic complication.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
